Skip to content
  • About us
    • About Peptonic
    • Board of Directors
    • Team
    • V Academy
  • Products
    • VagiVital
    • Studies
  • Investors
    • Extraordinary General Meeting 2025
    • Financial information
    • Share Performance
    • Articles of association
    • Patents
    • Presentations
    • Analysis
  • Partnerships
  • Careers
  • Press & Media
    • Press releases and news
    • Presentations
  • Contact
  • English
    • Swedish
Menu
  • About us
    • About Peptonic
    • Board of Directors
    • Team
    • V Academy
  • Products
    • VagiVital
    • Studies
  • Investors
    • Extraordinary General Meeting 2025
    • Financial information
    • Share Performance
    • Articles of association
    • Patents
    • Presentations
    • Analysis
  • Partnerships
  • Careers
  • Press & Media
    • Press releases and news
    • Presentations
  • Contact
  • English
    • Swedish

Extraordinary General Meeting 2025

  • Investors
  • Financial information
  • Share Performance
  • Articles of association
  • Patents & trademarks
  • Presentations
  • Analysis
  • Investors
  • Financial information
  • Share Performance
  • Articles of association
  • Patents & trademarks
  • Presentations
  • Analysis

Extraordinary General Meeting 2025

The shareholders of PEPTONIC medical AB, reg. no. 556776-3064 (the “Company”), are hereby invited to an Extraordinary General Meeting on January 7, 2025 at 10.00 a.m. at the premises of Eversheds Sutherland Advokatbyrå at Sveavägen 20 in Stockholm. Registration starts at. 09.45.

pdf_symbol_35pxNotice of Extraordinary General Meeting in PEPTONIC medical AB (Swedish)
pdf_symbol_35pxThe board’s report pursuant to Chapter 13. Section 6 of the Companies Act for significant events (Swedish)
pdf_symbol_35pxThe auditor’s opinion under Chapter 13. Section 6 of the Swedish Companies Act (2005:551) on the Board of Directors’ report on significant events for the period May 21, 2024 – November 28, 2024 (Swedish)
pdf_symbol_35pxThe auditor’s opinion under Chapter 13. Section 6 of the Swedish Companies Act (2005:551) on the Board of Directors’ report on significant events for the period April 30, 2024 – November 28, 2024 (Swedish)
pdf_symbol_35pxArticles of Association 1 (Swedish)
pdf_symbol_35pxArticles of Association 2 (Swedish)
pdf_symbol_35pxProxy form

The board’s report pursuant to Chapter 20. Section 13 of the Companies Act (Swedish)

The auditor’s opinion under Chapter 20. Section 14 of the Swedish Companies Act (Swedish)

PrevPreviousTeam
  • +46 8 530 20 110
  • info@peptonicmedical.se
  • Färögatan 33
    SE-164 53
    Kista, Sweden

NAVIGATION

  • About us
    • About Peptonic
    • Board of Directors
    • Team
    • V Academy
  • Products
    • VagiVital
    • Studies
  • Investors
    • Extraordinary General Meeting 2025
    • Financial information
    • Share Performance
    • Articles of association
    • Patents
    • Presentations
    • Analysis
  • Partnerships
  • Careers
  • Press & Media
    • Press releases and news
    • Presentations
  • Contact
  • English
    • Swedish
Menu
  • About us
    • About Peptonic
    • Board of Directors
    • Team
    • V Academy
  • Products
    • VagiVital
    • Studies
  • Investors
    • Extraordinary General Meeting 2025
    • Financial information
    • Share Performance
    • Articles of association
    • Patents
    • Presentations
    • Analysis
  • Partnerships
  • Careers
  • Press & Media
    • Press releases and news
    • Presentations
  • Contact
  • English
    • Swedish

WANT US TO CONTACT YOU?

© All rights reserved

Privacy Policy

Twitter Facebook Dribbble Youtube Pinterest Medium